In a preclinical NSCLC in vivo model, AZD4205 treatment inhibited tumor growth and STAT3 activation; these findings were more significant when AZD4205 was administered in combination with the EGFR inhibitor osimertinib. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.